Correction: Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors (Proceedings of the National Academy of Sciences (2019) 116 (619-624) DOI: 10.1073/pnas.1814027116)

Charles Li, Elena Bonazzoli, Stefania Bellone, Jungmin Choi, Weilai Dong, Gulden Menderes, Gary Altwerger, Chanhee Han, Aranzazu Manzano, Anna Bianchi, Francesca Pettinella, Paola Manara, Salvatore Lopez, Ghanshyam Yadav, Francesco Riccio, Luca Zammataro, Burak Zeybek, Yang Yang-Hartwich, Natalia Buza, Pei HuiSerena Wong, Antonella Ravaggi, Eliana Bignotti, Chiara Romani, Paola Todeschini, Laura Zanotti, Valentina Zizioli, Franco Odicino, Sergio Pecorelli, Laura Ardighieri, Dan Arin Silasi, Babak Litkouhi, Elena Ratner, Masoud Azodi, Gloria S. Huang, Peter E. Schwartz, Richard P. Lifton, Joseph Schles-singer, Alessandro D. Santin

Research output: Contribution to journalComment/debatepeer-review

1 Citation (Scopus)

Abstract

Correction for “Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors,” by Charles Li, Elena Bonazzoli, Stefania Bellone, Jungmin Choi, Weilai Dong, Gulden Menderes, Gary Altwerger, Chanhee Han, Aranzazu Manzano, Anna Bianchi, Francesca Pettinella, Paola Manara, Salvatore Lopez, Ghanshyam Yadav, Francesco Riccio, Luca Zammataro, Burak Zeybek, Yang Yang-Hartwich, Natalia Buza, Pei Hui, Serena Wong, Antonella Ravaggi, Eliana Bignotti, Chiara Romani, Paola Todeschini, Laura Zanotti, Valentina Zizioli, Franco Odicino, Sergio Pecorelli, Laura Ardighieri, Dan-Arin Silasi, Babak Litkouhi, Elena Ratner, Masoud Azodi, Gloria S. Huang, Peter E. Schwartz, Richard P. Lifton, Joseph Schlessinger, and Alessandro D. Santin, which was first published December 24, 2018; 10.1073/pnas.1814027116 (Proc Natl Acad Sci USA 116:619–624). The authors note that the following statement should be added to the Acknowledgments: “This work was also supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Ovarian Cancer Research Program under Award W81XWH-15-1-0221 (to Y.Y.-H.).”

Original languageEnglish
Pages (from-to)5829
Number of pages1
JournalProceedings of the National Academy of Sciences of the United States of America
Volume116
Issue number12
DOIs
Publication statusPublished - 2019

Bibliographical note

Publisher Copyright:
© 2019 National Academy of Sciences. All rights reserved.

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Correction: Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors (Proceedings of the National Academy of Sciences (2019) 116 (619-624) DOI: 10.1073/pnas.1814027116)'. Together they form a unique fingerprint.

Cite this